RT Journal Article
SR Electronic
T1 Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 923
OP 931
DO 10.21873/anticanres.13195
VO 39
IS 2
A1 KOICHI SARUWATARI
A1 TOKUNORI IKEDA
A1 SHO SAEKI
A1 NAOKI SHINGU
A1 KOSUKE IMAMURA
A1 TAIYOU KOMATU
A1 SUNAO USHIJIMA
A1 HIROTAKA MARUYAMA
A1 KOSUKE KASHIWABARA
A1 YUSUKE TOMITA
A1 HIDENORI ICHIYASU
A1 KAZUHIKO FUJII
A1 TAKURO SAKAGAMI
YR 2019
UL http://ar.iiarjournals.org/content/39/2/923.abstract
AB Background/Aim: The optimal treatment strategy for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) has not yet been fully determined. The aim of this study was to investigate the optimal management of EGFR-mutant NSCLC patients with BM. Patients and Methods: A multicenter retrospective study was performed on the clinical outcomes of 81 advanced/recurrent EGFR-mutant NSCLC patients with BM treated with EGFR–tyrosine kinase inhibitors (EGFR-TKIs) (gefitinib n=52 or erlotinib n=29). Results: Among the 81 patients, 30 patients received upfront cranial radiotherapy (CRT) and 51 did not. The multivariate cox analyses revealed that the use of erlotinib and upfront CRT were independent predictive factors for overall survival (OS) (erlotinib: HR 0.21; 95% CI, 0.10-0.48; p<0.001; upfront CRT: HR 0.42; 95% CI, 0.20-0.88; p=0.022). Conclusion: Erlotinib and upfront CRT were associated with a favorable prognosis among EGFR-mutant NSCLC patients with BM. Upfront CRT followed by erlotinib may be an appropriate initial management approach for EGFR-mutant NSCLC patients with BM.